ENA Respiratory has started dosing participants in its phase 2 community study of INNA‑051, a dry‑powder nasal spray designed to strengthen the body’s natural antiviral defences and reduce the impact ...

Akari Therapeutics has filed a new US provisional patent covering AKTX-102, its second antibody drug conjugate targeting ...

Gedeon Richter UK has assumed full marketing and distribution responsibilities for the neuropsychiatry medicine cariprazine ...

Corcept Therapeutics, a pharmaceutical company specialising in cortisol-modulating medications, has announced that its ...

The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

CERo has released new findings from its ongoing phase 1 CertainT‑1 study evaluating CER‑1236, a first‑in‑human chimeric ...

Astellas Pharma has announced that the Scottish Medicines Consortium has accepted zolbetuximab for use on the NHS in Scotland ...

ErVimmune, a preclinical biotechnology company focused on the development of cell therapies and cancer vaccines, has ...

Nxera Pharma has reported encouraging top-line data from a phase 3 clinical trial of its insomnia treatment daridorexant in ...

Venner Shipley, an intellectual property (IP) law firm with focuses including life sciences, pharmaceuticals and medtech, has ...

Argo Biopharma has announced that the first patient has been dosed in a global phase 2b clinical trial of BW‑20829, an siRNA therapy being evaluated in adults with elevated lipoprotein (a) and ...

BioMed X, a leading innovation hub for pharma, has announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s ...